Abstract Submission Guidelines

The Scientific Planning Committee will evaluate the scientific quality of the submitted abstracts based on the following criteria: novelty of the research, significance of the findings, and clarity. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear, succinct manner and of summarizing the new, unpublished results. If an abstract is poorly written such that the Scientific Planning Committee cannot determine its novelty and importance, the paper will not be accepted for presentation at the conference.

Authors submitting abstracts for presentation at this conference should consider the following:

1. Each submitting author may submit no more than two abstracts
2. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, originality, and comprehensiveness of the work can be evaluated by the Scientific Planning Committee. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of the pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statement in their abstracts. American spelling should be used throughout.
3. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate electronic retrieval (if applicable). Avoid nonstandard abbreviations in abstract titles.
4. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified.
5. The length of the abstract body may not exceed 4,000 characters (including spaces). The online submitter will not accept abstracts that exceed this limit. The title and the author and institution list are not included in the character limit. Tables, graphs, and images are not permitted.
6. When biological or chemical data pertaining to chemical entities are an integral part of the research, the chemical structure, method of preparation, and patent or reference numbers must be presented. If or any reason this information cannot be provided when the paper is presented at the conference, the abstract on this work should not be submitted for consideration.
7. Because of administrative and time constraints, supplemental data cannot be considered by the Scientific Planning Committee.
8. The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to publish the abstract exactly as submitted. Authors should prepare and proofread their abstracts carefully prior to submission. Errors made on your submitted abstracts are likely to appear in print.

9. Authors are strongly encouraged to print a hard copy of their abstracts before submitting.

10. All presenters must register to attend the conference.

11. If an abstract is accepted and the presenter does not register, the abstract may be withdrawn.

12. Abstract submitters will receive a confirmation email upon submission. Additional information, status, and scheduling details will also be sent to email address provided for the submitters.

13. Abstract may only be submitted through the online abstract submission platform. Only those abstracts that have been reviewed and selected by the Scientific Planning Committee may be presented. Please be sure to carefully check your abstract for content errors, spelling, names, etc. before submitting. The organizers do not proofread or correct spelling, typographical, grammatical, or scientific errors, nor can changes be made once the abstract is submitted. For technical questions or if you have policy related questions, please contact the abstract submission help desk at abstracts@cancerimmunotherapyconference.org